FTC Tells Medtronic To Sell Intersect ENT Subsidiary To Avoid Monopoly
The move removes all regulatory roadblocks to Medtronic’s $1.1bn acquisition of Intersect ENT, which was announced in August 2021.
You may also be interested in...
Medtronic announced plans to acquire Intersect ENT, adding its sinus implants to Medtronic's portfolio of devices used by surgeons in treating chronic rhinosinusitis.
The user fee package was among several health-related bills that the subcommittee took up on Wednesday.
The jury said the infringement, which involved patents on two-channel sequencing chemistry technology, had been “willful” and turned down Illumina’s counterclaims.